Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 7.446
Filter
1.
Mycoses ; 67(6): e13751, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38825584

ABSTRACT

BACKGROUND: Kerion is a severe type of tinea capitis that is difficult to treat and remains a public health problem. OBJECTIVES: To evaluate the epidemiologic features and efficacy of different treatment schemes from real-world experience. METHODS: From 2019 to 2021, 316 patients diagnosed with kerion at 32 tertiary Chinese hospitals were enrolled. We analysed the data of each patient, including clinical characteristics, causative pathogens, treatments and outcomes. RESULTS: Preschool children were predominantly affected and were more likely to have zoophilic infection. The most common pathogen in China was Microsporum canis. Atopic dermatitis (AD), animal contact, endothrix infection and geophilic pathogens were linked with kerion occurrence. In terms of treatment, itraconazole was the most applied antifungal agent and reduced the time to mycological cure. A total of 22.5% of patients received systemic glucocorticoids simultaneously, which reduced the time to complete symptom relief. Furthermore, glucocorticoids combined with itraconazole had better treatment efficacy, with a higher rate and shorter time to achieving mycological cure. CONCLUSIONS: Kerion often affects preschoolers and leads to serious sequelae, with AD, animal contact, and endothrix infection as potential risk factors. Glucocorticoids, especially those combined with itraconazole, had better treatment efficacy.


Subject(s)
Antifungal Agents , Itraconazole , Microsporum , Tinea Capitis , Humans , Child, Preschool , Antifungal Agents/therapeutic use , Male , Female , Tinea Capitis/drug therapy , Tinea Capitis/epidemiology , Tinea Capitis/microbiology , Itraconazole/therapeutic use , China/epidemiology , Microsporum/isolation & purification , Child , Infant , Glucocorticoids/therapeutic use , Treatment Outcome , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/epidemiology , Dermatitis, Atopic/microbiology , Risk Factors , Adolescent , Adult , Middle Aged , Retrospective Studies
2.
Mycopathologia ; 189(4): 53, 2024 Jun 12.
Article in English | MEDLINE | ID: mdl-38864961

ABSTRACT

Sporotrichosis is a globally distributed subcutaneous mycosis caused by dimorphic Sporothrix species commonly found in soil, mosses, and decaying plant matter. The lymphocutaneous manifestation, historically associated with occupational activities and sapronotic transmission, has recently been observed to also occur through animal contact, particularly notable in Brazil. We describe a rare case of lymphocutaneous sporotrichosis with simultaneous pulmonary complications resulting from the scratching of a southern three-banded armadillo, Tolypeutes matacus, primarily inhabiting the arid forests of South America's central region. Speciation using multiplex quantitative polymerase chain reaction (qPCR) established the etiological agent as S. schenckii s. str., while amplified fragment length polymorphism (AFLP) analysis unveiled a novel genotype circulating in the Midwest of Brazil. The patient received treatment with itraconazole (200 mg/day) for two months, leading to substantial clinical improvement of cutaneous and pulmonary symptoms. This case highlights the critical role of animal-mediated transmission in sporotrichosis epidemiology, particularly within regions with diverse armadillo species. The unusual epidemiology and genetic characteristics of this case emphasize the need for enhanced awareness and diagnostic vigilance in atypical sporotrichosis presentations.


Subject(s)
Antifungal Agents , Armadillos , Itraconazole , Sporothrix , Sporotrichosis , Sporotrichosis/microbiology , Sporotrichosis/diagnosis , Sporotrichosis/drug therapy , Sporotrichosis/transmission , Armadillos/microbiology , Brazil , Humans , Sporothrix/genetics , Sporothrix/isolation & purification , Sporothrix/classification , Animals , Antifungal Agents/therapeutic use , Male , Itraconazole/therapeutic use , Genotype , Amplified Fragment Length Polymorphism Analysis , Treatment Outcome , Multiplex Polymerase Chain Reaction
3.
Mycopathologia ; 189(4): 54, 2024 Jun 12.
Article in English | MEDLINE | ID: mdl-38865003

ABSTRACT

BACKGROUND: During the COVID-19 pandemic-associated mucor epidemic, acute antifungal drug shortage necessitated the exploration of other antifungals based on culture sensitivity. Itraconazole is a cheap, safe, and effective antifungal in sensitive cases. METHODOLOGY: We enrolled itraconazole-sensitive COVID-19-associated mucormycosis during the mucormycosis pandemic. After the intensive phase course of liposomal amphotericin B, Itraconazole was offered in susceptible cases during the maintenance phase along with standard of care. These patients were clinically and radiologically followed for 6 months. RESULTS: We enrolled 14 patients (Male: Female-11:3) of Rhino-orbito-cerebral mucormycosis (ROCM) which included 12 diabetics. All patients had facial swelling, orbital swelling, visual impairment, and headache. MRI showed involvement of bilateral sinus (10/14), orbital extension (13/14), cavernous sinus (5/14), cerebral part of the internal carotid artery (3/14), and brain infarcts (4/14). All 14 patients showed sensitivity to Itraconazole with 12 having minimum inhibitory concentration (MIC) ≤ 1 µg/ml and 2 having MIC ≤ 2 µg/ml. Follow-up at 6 months showed clinical improvement in the majority (11/14) and radiological improvement in six out of seven scanned patients. CONCLUSION: Our study shows the potential therapeutic role of oral Itraconazole in ROCM.


Subject(s)
Amphotericin B , Antifungal Agents , Itraconazole , Mucormycosis , Rhizopus oryzae , Humans , Male , Itraconazole/therapeutic use , Itraconazole/administration & dosage , Female , Mucormycosis/drug therapy , Amphotericin B/therapeutic use , Amphotericin B/administration & dosage , Antifungal Agents/therapeutic use , Antifungal Agents/administration & dosage , Middle Aged , Adult , Rhizopus oryzae/drug effects , Microbial Sensitivity Tests , COVID-19/complications , Aged , Drug Therapy, Combination , Treatment Outcome
5.
Mycopathologia ; 189(3): 44, 2024 May 11.
Article in English | MEDLINE | ID: mdl-38734862

ABSTRACT

A 50-year-old man, previously diagnosed with pulmonary tuberculosis and lung cavities, presented with symptoms including fever, shortness of breath, and cough. A pulmonary CT scan revealed multiple cavities, consolidation and tree-in-bud in the upper lungs. Further investigation through direct examination of bronchoalveolar lavage fluid showed septate hyphae with dichotomous acute branching. Subsequent isolation and morphological analysis identified the fungus as belonging to Aspergillus section Nigri. The patient was diagnosed with probable invasive pulmonary aspergillosis and successfully treated with a three-month oral voriconazole therapy. Phylogenetic analysis based on partial ß-tubulin, calmodulin and RNA polymerase second largest subunit sequences revealed that the isolate represents a putative new species related to Aspergillus brasiliensis, and is named Aspergillus hubkae here. Antifungal susceptibility testing demonstrated that the isolate is resistant to itraconazole but susceptible to voriconazole. This phenotypic and genetic characterization of A. hubkae, along with the associated case report, will serve as a valuable resource for future diagnoses of infections caused by this species. It will also contribute to more precise and effective patient management strategies in similar clinical scenarios.


Subject(s)
Antifungal Agents , Aspergillus , Invasive Pulmonary Aspergillosis , Microbial Sensitivity Tests , Phylogeny , Sequence Analysis, DNA , Voriconazole , Humans , Male , Middle Aged , Antifungal Agents/therapeutic use , Antifungal Agents/pharmacology , Aspergillus/isolation & purification , Aspergillus/genetics , Aspergillus/classification , Aspergillus/drug effects , Bronchoalveolar Lavage Fluid/microbiology , Cluster Analysis , DNA, Fungal/genetics , DNA, Fungal/chemistry , Invasive Pulmonary Aspergillosis/microbiology , Invasive Pulmonary Aspergillosis/drug therapy , Invasive Pulmonary Aspergillosis/diagnosis , Itraconazole/pharmacology , Microscopy , Tomography, X-Ray Computed , Treatment Outcome , Tubulin/genetics , Voriconazole/therapeutic use , Voriconazole/pharmacology
6.
Acta Trop ; 255: 107237, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38723739

ABSTRACT

The surge in domestic cat adoption across India, particularly the rising preference for high-pedigree cats, coupled with environmental factors, has resulted in increased incidence of dermatophytosis among feline companions. Despite this growing concern, there is a noticeable scarcity of studies in India delving into the etiological factors contributing to dermatophytosis in cats. This disease is a threat to animal health and carries public health significance, given that cats are recognized reservoir hosts for Microsporum canis, a common dermatophyte affecting humans and animals. This study endeavours to identify the dermatophytes affecting cats and establish a standardized therapeutic regimen while accounting for the local stigma surrounding the regular bathing of cats. The study involved the examination of 82 cats presenting dermatological lesions, when subjected to cultural examination in dermatophyte test medium revealed 36 afflicted with dermatophytes. Isolates were presumptively identified by staining using lactophenol cotton blue, Chicago sky blue 6B, and Calcofluor white stains. Molecular-level identification of the isolates was confirmed through PCR-RFLP, amplifying the Internal Transcribed Spacer Sequence of 16 s rDNA, followed by restriction digestion using the Mva1 enzyme. Among the thirty-six isolates, 29 were identified as M. canis, while the remaining 7 were M. gypseum. The cases were categorized into five groups and treated with Lime Sulphur dip, 4 % chlorhexidine shampoo, a shampoo containing 2 % miconazole and 4 % chlorhexidine, oral itraconazole alone, and a combination of oral itraconazole with lime-Sulphur dip. Statistical analysis revealed that the response was notably swifter with lime Sulphur dip when considering only topical therapy. Moreover, the mycological cure was most expeditious when combining Lime Sulphur dip with oral itraconazole. These findings underscore the pivotal role of topical biocides in feline dermatophytosis treatment, potentially reducing the reliance on specific antifungals and thereby contributing to the mitigation of antimicrobial resistance emergence.


Subject(s)
Antifungal Agents , Cat Diseases , Microsporum , Tinea , Cats/microbiology , Animals , Cat Diseases/microbiology , Cat Diseases/drug therapy , India/epidemiology , Tinea/veterinary , Tinea/microbiology , Tinea/drug therapy , Tinea/epidemiology , Antifungal Agents/therapeutic use , Microsporum/isolation & purification , Microsporum/genetics , Male , Female , Arthrodermataceae/isolation & purification , Arthrodermataceae/genetics , Arthrodermataceae/classification , Arthrodermataceae/drug effects , Itraconazole/therapeutic use , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , DNA, Fungal/genetics , DNA, Ribosomal Spacer/genetics
7.
Mol Pharm ; 21(6): 3027-3039, 2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38755753

ABSTRACT

This study presents a novel approach by utilizing poly(vinylpyrrolidone)s (PVPs) with various topologies as potential matrices for the liquid crystalline (LC) active pharmaceutical ingredient itraconazole (ITZ). We examined amorphous solid dispersions (ASDs) composed of ITZ and (i) self-synthesized linear PVP, (ii) self-synthesized star-shaped PVP, and (iii) commercial linear PVP K30. Differential scanning calorimetry, X-ray diffraction, and broad-band dielectric spectroscopy were employed to get a comprehensive insight into the thermal and structural properties, as well as global and local molecular dynamics of ITZ-PVP systems. The primary objective was to assess the influence of PVPs' topology and the composition of ASD on the LC ordering, changes in the temperature of transitions between mesophases, the rate of their restoration, and finally the solubility of ITZ in the prepared ASDs. Our research clearly showed that regardless of the PVP type, both LC transitions, from smectic (Sm) to nematic (N) and from N to isotropic (I) phases, are effectively suppressed. Moreover, a significant difference in the miscibility of different PVPs with the investigated API was found. This phenomenon also affected the solubility of API, which was the greatest, up to 100 µg/mL in the case of starPVP 85:15 w/w mixture in comparison to neat crystalline API (5 µg/mL). Obtained data emphasize the crucial role of the polymer's topology in designing new pharmaceutical formulations.


Subject(s)
Calorimetry, Differential Scanning , Itraconazole , Liquid Crystals , Povidone , Solubility , X-Ray Diffraction , Itraconazole/chemistry , Liquid Crystals/chemistry , Povidone/chemistry , Calorimetry, Differential Scanning/methods , X-Ray Diffraction/methods , Polymers/chemistry , Antifungal Agents/chemistry , Drug Compounding/methods , Crystallization , Chemistry, Pharmaceutical/methods
8.
Mycopathologia ; 189(2): 30, 2024 Apr 05.
Article in English | MEDLINE | ID: mdl-38578519

ABSTRACT

OBJECTIVE: To study the distribution of pathogenic Aspergillus strains of otomycosis in central China and the identification of their antifungal sensitivity. METHODS: We collected external ear canal secretions clinically diagnosed as otomycosis from April 2020 to January 2023 from the Department of Otolaryngology-Head and Neck Surgery in central China. The pathogenic Aspergillus strains were identified through morphological examination and sequencing. The antifungal sensitivity was performed using the broth microdilution method described in the Clinical Laboratory Standard Institute document M38-A3. RESULTS: In the 452 clinical strains isolated from the external ear canal, 284 were identified as Aspergillus terreus (62.83%), 92 as Aspergillus flavus (20.35%), 55 as Aspergillus niger (12.17%). In antifungal susceptibility tests the MIC of Aspergillus strains to bifonazole and clotrimazole was high,all the MIC90 is > 16 ug/mL. However, most Aspergillus isolates show moderate greatly against terbinafine, itraconazole and voriconazole. CONCLUSION: A. terreus is the most common pathogenic Aspergillus strain in otomycosis in central China. The selected topical antifungal drugs were bifonazole and clotrimazole; the drug resistance rate was approximately 30%. If the infection is persistent and requires systemic treatment, terbinafine and itraconazole can be used. The resistance of Aspergillus in otomycosis to voriconazole should be screened to avoid the systemic spread of infection in immunocompromised people and poor compliance with treatment. However, the pan-azole-resistant strain of Aspergillus should be monitored, particularly in high-risk patients with otomycosis.


Subject(s)
Aspergillosis , Otomycosis , Humans , Antifungal Agents/pharmacology , Otomycosis/epidemiology , Otomycosis/microbiology , Itraconazole , Voriconazole , Terbinafine , Clotrimazole/pharmacology , Aspergillosis/epidemiology , Aspergillosis/microbiology , Aspergillus , Microbial Sensitivity Tests
9.
Int J Biol Macromol ; 267(Pt 2): 131404, 2024 May.
Article in English | MEDLINE | ID: mdl-38582466

ABSTRACT

Chitosan has received much more attention as a functional biopolymer with applications in pharmaceuticals, agricultural, drug delivery systems and cosmetics. The objectives of present investigation were to carry out modification of chitosan for enhancement of aqueous solubility, which will impart increased solubility and dissolution rate of poorly soluble drug itraconazole (ITZ) and also evaluate the modified chitosan for soyabean seed germination studies. The modification of chitosan was accomplished through the antisolvent precipitation method; employing five carboxylic acids. The resulting products were assessed for changes in molecular weight, degree of deacetylation, solubility and solid state characterization. Subsequently, the modified chitosan was complexed with itraconazole using the co-grinding technique. The prepared formulations were evaluated for solubility, FTIR (Fourier-transform infrared spectroscopy), PXRD (Powder X-ray diffraction), in-vitro dissolution studies. Furthermore the effect of modified chitosan has been evaluated on soybean seed germination. Results demonstrated that, modified chitosan improves self and solubility of itraconazole by six folds. As there was increased degree of deacetylation of chitosan leads to improvement in solubility. The results of FTIR showed the slight shifting of peaks in co-grind formulations of itraconazole. Formulations showed reduction in crystallinity of drug which leads to enhancement in dissolution rate as compared to pure itraconazole. Retention of property of seed germination was observed with modified chitosan at optimum concentration of 3 % w/v, with benefit of enhanced aqueous solubility of chitosan. This positive result paves the way for the advancement of pharmaceutical and agrochemical products employing derivatives of chitosan.


Subject(s)
Agrochemicals , Chitosan , Itraconazole , Solubility , Chitosan/chemistry , Agrochemicals/chemistry , Agrochemicals/pharmacology , Itraconazole/chemistry , Itraconazole/pharmacology , Glycine max/chemistry , Germination/drug effects , Seeds/chemistry , Seeds/drug effects , Chemical Phenomena , Spectroscopy, Fourier Transform Infrared , Molecular Weight , X-Ray Diffraction
10.
Mar Drugs ; 22(4)2024 Apr 16.
Article in English | MEDLINE | ID: mdl-38667795

ABSTRACT

This open-label, two-part, phase Ib drug-drug interaction study investigated whether the pharmacokinetic (PK) and safety profiles of lurbinectedin (LRB), a marine-derived drug, are affected by co-administration of itraconazole (ITZ), a strong CYP3A4 inhibitor, in adult patients with advanced solid tumors. In Part A, three patients were sequentially assigned to Sequence 1 (LRB 0.8 mg/m2, 1-h intravenous [IV] + ITZ 200 mg/day oral in Cycle 1 [C1] and LRB alone 3.2 mg/m2, 1 h, IV in Cycle 2 [C2]). In Part B, 11 patients were randomized (1:1) to receive either Sequence 1 (LRB at 0.9 mg/m2 + ITZ in C1 and LRB alone in C2) or Sequence 2 (LRB alone in C1 and LRB + ITZ in C2). Eleven patients were evaluable for PK analysis: three in Part A and eight in Part B (four per sequence). The systemic total exposure of LRB increased with ITZ co-administration: 15% for Cmax, area under the curve (AUC) 2.4-fold for AUC0-t and 2.7-fold for AUC0-∞. Co-administration with ITZ produced statistically significant modifications in the unbound plasma LRB PK parameters. The LRB safety profile was consistent with the toxicities described in previous studies. Co-administration with multiple doses of ITZ significantly altered LRB systemic exposure. Hence, to avoid LRB overexposure when co-administered with strong CYP3A4 inhibitors, an LRB dose reduction proportional to CL reduction should be applied.


Subject(s)
Carbolines , Cytochrome P-450 CYP3A Inhibitors , Drug Interactions , Heterocyclic Compounds, 4 or More Rings , Itraconazole , Neoplasms , Humans , Itraconazole/pharmacokinetics , Itraconazole/administration & dosage , Itraconazole/adverse effects , Male , Middle Aged , Female , Aged , Neoplasms/drug therapy , Heterocyclic Compounds, 4 or More Rings/pharmacokinetics , Heterocyclic Compounds, 4 or More Rings/administration & dosage , Heterocyclic Compounds, 4 or More Rings/adverse effects , Cytochrome P-450 CYP3A Inhibitors/administration & dosage , Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Carbolines/pharmacokinetics , Carbolines/administration & dosage , Carbolines/adverse effects , Adult , Heterocyclic Compounds, 3-Ring/pharmacokinetics , Heterocyclic Compounds, 3-Ring/administration & dosage , Heterocyclic Compounds, 3-Ring/adverse effects , Area Under Curve , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/adverse effects , Antineoplastic Agents/administration & dosage
11.
Expert Opin Pharmacother ; 25(5): 511-519, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38623728

ABSTRACT

INTRODUCTION: The reports of resistance to antifungal agents used for treating onychomycosis and other superficial fungal infections are increasing. This rise in antifungal resistance poses a public health challenge that requires attention. AREAS COVERED: This review explores the prevalence of dermatophytes and the current relationship between dermatophyte species, their minimum inhibitory concentrations (MICs) for terbinafine (an allylamine) and itraconazole (an azole), and various mutations prevalent in these species. The most frequently isolated dermatophyte associated with resistance in patients with onychomycosis and dermatophytosis was T. mentagrophytes. However, T. indotineae emerged as the most prevalent isolate with mutations in the SQLE gene, exhibiting the highest MIC of 8 µg/ml for terbinafine and MICs of 8 µg/ml and ≥ 32 µg/ml for itraconazole.Overall, the most prevalent SQLE mutations were Phe397Leu, Leu393Phe, Ala448Thr, Phe397Leu/Ala448Thr, and Lys276Asn/Leu415Phe (relatively recent). EXPERT OPINION: Managing dermatophyte infections requires a personalized approach. A detailed history should be obtained including details of travel, home and occupational exposure, and clinical examination of the skin, nails and other body systems. Relevant testing includes mycological examination (traditional and molecular). Additional testing, where available, includes MIC evaluation and detection of SQLE mutations. In case of suspected terbinafine resistance, itraconazole or voriconazole (less commonly) should be considered.


Subject(s)
Antifungal Agents , Arthrodermataceae , Drug Resistance, Fungal , Microbial Sensitivity Tests , Mutation , Terbinafine , Tinea , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Humans , Drug Resistance, Fungal/genetics , Tinea/drug therapy , Tinea/microbiology , Arthrodermataceae/drug effects , Arthrodermataceae/genetics , Terbinafine/pharmacology , Terbinafine/therapeutic use , Itraconazole/pharmacology , Itraconazole/therapeutic use , Onychomycosis/drug therapy , Onychomycosis/microbiology
12.
Microbiol Spectr ; 12(6): e0396723, 2024 Jun 04.
Article in English | MEDLINE | ID: mdl-38647345

ABSTRACT

Acylhydrazone (AH) derivatives represent a novel category of anti-fungal medications that exhibit potent activity against Sporothrix sp., both in vitro and in a murine model of sporotrichosis. In this study, we demonstrated the anti-fungal efficacy of the AH derivative D13 [4-bromo-N'-(3,5-dibromo-2-hydroxybenzylidene)-benzohydrazide] against both planktonic cells and biofilms formed by Sporothrix brasiliensis. In a clinical study, the effect of D13 was then tested in combination with itraconazole (ITC), with or without potassium iodide, in 10 cats with sporotrichosis refractory to the treatment of standard of care with ITC. Improvement or total clinical cure was achieved in five cases after 12 weeks of treatment. Minimal abnormal laboratory findings, e.g., elevation of alanine aminotransferase, were observed in four cats during the combination treatment and returned to normal level within a week after the treatment was ended. Although highly encouraging, a larger and randomized controlled study is required to evaluate the effectiveness and the safety of this new and exciting drug combination using ITC and D13 for the treatment of feline sporotrichosis. IMPORTANCE: This paper reports the first veterinary clinical study of an acylhydrazone anti-fungal (D13) combined with itraconazole against a dimorphic fungal infection, sporotrichosis, which is highly endemic in South America in animals and humans. Overall, the results show that the combination treatment was efficacious in ~50% of the infected animals. In addition, D13 was well tolerated during the course of the study. Thus, these results warrant the continuation of the research and development of this new class of anti-fungals.


Subject(s)
Antifungal Agents , Cat Diseases , Drug Therapy, Combination , Itraconazole , Sporothrix , Sporotrichosis , Cats , Animals , Itraconazole/therapeutic use , Itraconazole/administration & dosage , Itraconazole/pharmacology , Sporotrichosis/drug therapy , Sporotrichosis/veterinary , Antifungal Agents/therapeutic use , Antifungal Agents/pharmacology , Antifungal Agents/administration & dosage , Cat Diseases/drug therapy , Cat Diseases/microbiology , Sporothrix/drug effects , Hydrazones/therapeutic use , Hydrazones/pharmacology , Female , Male , Microbial Sensitivity Tests , Biofilms/drug effects , Treatment Outcome
14.
Molecules ; 29(8)2024 Apr 13.
Article in English | MEDLINE | ID: mdl-38675589

ABSTRACT

The aim of this study was to develop cholic-acid-stabilized itraconazole nanosuspensions (ITZ-Nanos) with the objective of enhancing drug dissolution and oral absorption. A laboratory-scale microprecipitation-high-pressure homogenization method was employed for the preparation of the ITZ-Nanos, while dynamic light scattering, transmission electron microscope analysis, X-ray diffraction, differential scanning calorimetry, and high-performance liquid chromatography analysis were utilized to evaluate their physicochemical properties. The absorption and bioavailability of the ITZ-Nanos were assessed using Caco-2 cells and rats, with Sporanox® pellets as a comparison. Prior to lyophilization, the particle size of the ITZ-Nanos measured approximately 225.7 nm. Both X-ray diffraction and differential scanning calorimetry confirmed that the ITZ remained crystalline within the nanocrystals. Compared to the pellets, the ITZ-Nanos exhibited significantly higher levels of supersaturation dissolution and demonstrated enhanced drug uptake by the Caco-2 cells. The AUC(0-t) value for the ITZ-Nanos in rats was 1.33-fold higher than that observed for the pellets. These findings suggest that cholic acid holds promise as a stabilizer for ITZ nanocrystals, as well as potentially other nanocrystals.


Subject(s)
Itraconazole , Nanoparticles , Solubility , Surface-Active Agents , Itraconazole/chemistry , Itraconazole/pharmacokinetics , Itraconazole/administration & dosage , Nanoparticles/chemistry , Humans , Caco-2 Cells , Animals , Rats , Administration, Oral , Surface-Active Agents/chemistry , Male , Biological Availability , Particle Size , X-Ray Diffraction , Calorimetry, Differential Scanning , Cholic Acid/chemistry
15.
Mycoses ; 67(4): e13724, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38584320

ABSTRACT

OBJECTIVE: This study aims to assess the clinical characteristics of sporotrichosis in low-endemic areas of China, including the prevalence geography, genotypic traits of patients, clinical manifestations, and strain virulence and drug sensitivities. The objective is to improve the currently used clinical management strategies for sporotrichosis. METHODS: Retrospective data were collected from patients diagnosed with sporotrichosis through fungal culture identification. The isolates from purified cultures underwent identification using CAL (Calmodulin) gene sequencing. Virulence of each strain was assessed using a Galleria mellonella (G. mellonella) larvae infection model. In vitro susceptibility testing against commonly used clinical antifungal agents for sporotrichosis was conducted following CLSI criteria. RESULTS: In our low-endemic region for sporotrichosis, the majority of cases (23) were observed in middle-aged and elderly women with a history of trauma, with a higher incidence during winter and spring. All clinical isolates were identified as Sporothrix globosa (S. globosa). The G. mellonella larvae infection model indicated independent and dose-dependent virulence among strains, with varying toxicity levels demonstrated by the degree of melanization of the G. mellonella. Surprisingly, lymphocutaneous types caused by S. globosa exhibited lower in vitro virulence but were more common in affected skin. In addition, all S.globosa strains displayed high resistances to fluconazole, while remaining highly susceptible to terbinafine, itraconazole and amphotericin B. CONCLUSION: Given the predominance of elderly women engaged in agricultural labour in our region, which is a low-epidemic areas, they should be considered as crucial targets for sporotrichosis monitoring. S. globosa appears to be the sole causative agent locally. However, varying degrees of melanization in larvae were observed among these isolates, indicating a divergence in their virulence. Itraconazole, terbinafine and amphotericin B remain viable first-line antifungal options for treating S.globosa infection.


Subject(s)
Sporothrix , Sporotrichosis , Aged , Middle Aged , Humans , Female , Itraconazole/pharmacology , Itraconazole/therapeutic use , Sporotrichosis/microbiology , Amphotericin B/pharmacology , Amphotericin B/therapeutic use , Terbinafine/therapeutic use , Retrospective Studies , Microbial Sensitivity Tests , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Sporothrix/genetics , China/epidemiology
16.
Drug Metab Pharmacokinet ; 55: 101000, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38458122

ABSTRACT

In this study, a physiologically based pharmacokinetic (PBPK) model of the cytochrome P450 3A (CYP3A) substrate azelnidipine was developed using in vitro and clinical data to predict the effects of azole antifungals on azelnidipine pharmacokinetics. Modeling and simulations were conducted using the Simcyp™ PBPK simulator. The azelnidipine model consisted of a full PBPK model and a first-order absorption model. CYP3A was assumed as the only azelnidipine elimination route, and CYP3A clearance was optimized using the pharmacokinetic profile of single-dose 5-mg azelnidipine in healthy participants. The model reproduced the results of a clinical drug-drug interaction study and met validation criteria. PBPK model simulations using azole antifungals (itraconazole, voriconazole, posaconazole, fluconazole, fosfluconazole) and azelnidipine or midazolam (CYP3A index substrate) were performed. Increases in the simulated area under the plasma concentration-time curve from time zero extrapolated to infinity with inhibitors were comparable between azelnidipine (range, 2.11-6.47) and midazolam (range, 2.26-9.22), demonstrating that azelnidipine is a sensitive CYP3A substrate. Increased azelnidipine plasma concentrations are expected when co-administered with azole antifungals, potentially affecting azelnidipine safety. These findings support the avoidance of azole antifungals in patients taking azelnidipine and demonstrate the utility of PBPK modeling to inform appropriate drug use.


Subject(s)
Antifungal Agents , Azetidinecarboxylic Acid/analogs & derivatives , Dihydropyridines , Midazolam , Humans , Midazolam/pharmacokinetics , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Cytochrome P-450 CYP3A , Drug Interactions , Itraconazole , Models, Biological
17.
BMJ Case Rep ; 17(3)2024 Mar 08.
Article in English | MEDLINE | ID: mdl-38458767

ABSTRACT

Eumycetoma, a subcutaneous infection caused by various fungi with pathognomonic discharging grain, is rarely reported in Malaysia. This case concerns a eumycetoma infection in an immunocompetent man who presented with progressive left foot swelling complicated with pustules, sinuses and pale grain discharge for the past year after recurrent thorn pricks. Histological findings of the grain and tissue showed foci of septate fungal hyphae. Tissue culture yielded no growth. Amplification and sequencing of the rDNA internal transcribed spacer 1 (ITS1), ITS4 and large subunit regions of the tissue identified the causative agent as Fusarium falciforme, highlighting the role of molecular diagnostic method in identifying fungal species in eumycetoma. The patient was treated with surgical excision and oral itraconazole with excellent improvement. However, he presented again with recurrence after defaulting therapy. F. falciforme has been implicated in causing diseases in crops and sea turtles. Therefore, the One Health approach should be adopted to manage this emerging species.


Subject(s)
Fusarium , Mycetoma , Male , Humans , Mycetoma/diagnosis , Mycetoma/drug therapy , Neglected Diseases , Itraconazole/therapeutic use
18.
BMJ Case Rep ; 17(3)2024 Mar 11.
Article in English | MEDLINE | ID: mdl-38471698

ABSTRACT

Abdominal masses clubbed with weight loss in the paediatric age group can raise hairs, especially since malignancy is a differential. We present the case of an early adolescent male who presented with abdominal pain and was found to have a mass mimicking a malignancy. The resected surgical specimen revealed entomophthoromycosis of the jejunum and he made a complete recovery following surgery and adjuvant itraconazole. The diagnosis of a fungal aetiology in these cases requires a high index of suspicion and background knowledge of the risk factors, disease occurrence and mode of presentation. Gastrointestinal entomophthoromycosis has an impressive potential for cure if promptly diagnosed and treated.


Subject(s)
Zygomycosis , Adolescent , Humans , Male , Abdominal Pain/etiology , Itraconazole , Neoplasms , Zygomycosis/diagnosis
19.
BMJ Case Rep ; 17(3)2024 Mar 15.
Article in English | MEDLINE | ID: mdl-38490708

ABSTRACT

Chromoblastomycosis is an implantation mycosis of the skin caused by certain species of melanised fungi. A man in his 50s, born in Kerala but living in England for 14 years, presented with a nodular lesion on his left buttock, which had been present for 20 years. Biopsy revealed muriform cells and fungal culture isolated Fonsecaea spp, consistent with a diagnosis of chromoblastomycosis. Treatment with oral terbinafine was initiated and changed to itraconazole based on results of antifungal susceptibility. Drug intolerance and low drug levels of itraconazole necessitated change to voriconazole and topical terbinafine. Despite long-term combined therapy, the lesions worsened, and the patient opted for surgical excision abroad. Recurrence was evident at surgical sites and combined therapy continues. Chromoblastomycosis is an insidious and burdensome neglected tropical disease. Within non-endemic countries, diagnosis remains challenging. A travel history and appropriate fungal investigations are vital.


Subject(s)
Ascomycota , Chromoblastomycosis , Male , Humans , Terbinafine/therapeutic use , Itraconazole/therapeutic use , Chromoblastomycosis/diagnosis , Chromoblastomycosis/drug therapy , Chromoblastomycosis/microbiology , Buttocks/pathology , Antifungal Agents/therapeutic use
20.
Emerg Infect Dis ; 30(4): 807-809, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38437706

ABSTRACT

We describe a case of tinea genitalis in an immunocompetent woman in Pennsylvania, USA. Infection was caused by Trichophyton indotineae potentially acquired through sexual contact. The fungus was resistant to terbinafine (first-line antifungal) but improved with itraconazole. Clinicians should be aware of T. indotineae as a potential cause of antifungal-resistant genital lesions.


Subject(s)
Antifungal Agents , Trichophyton , Female , Humans , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Drug Resistance, Fungal , Itraconazole/therapeutic use , Microbial Sensitivity Tests , Terbinafine/pharmacology , Terbinafine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...